Edgewise Therapeutics, Inc. Debt Securities, Available-for-sale, Unrealized Gain
Edgewise Therapeutics, Inc. (EWTX) reported Debt Securities, Available-for-sale, Unrealized Gain of $326.00 thousand for the 6-month period ending 2025-06-30, per its 10-Q filed 2025-08-07.
Financial Statements › Income Statement › Other Income
us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain · last filed 2025-08-07
- Edgewise Therapeutics, Inc. debt securities, available-for-sale, unrealized gain for the quarter ending 2025-06-30 was -$108.00K.
- Edgewise Therapeutics, Inc. debt securities, available-for-sale, unrealized gain for the quarter ending 2025-03-31 was $434.00K.
| Period end | Debt Securities, Available-for-sale, Unrealized Gain 3 month | Debt Securities, Available-for-sale, Unrealized Gain 6 month |
|---|---|---|
| 2025-06-30 | -$108.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $326.00K 10-Q · filed 2025-08-07 |
| 2025-03-31 | $434.00K 10-Q · filed 2025-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 |